Free Trial

Vigil Neuroscience (VIGL) Competitors

Vigil Neuroscience logo
$7.99 +0.01 (+0.13%)
Closing price 07/3/2025 02:36 PM Eastern
Extended Trading
$7.99 0.00 (0.00%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VIGL vs. BHVN, ETNB, ANIP, VERA, JANX, EVO, OCUL, MESO, TVTX, and BGM

Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

Vigil Neuroscience vs. Its Competitors

Vigil Neuroscience (NASDAQ:VIGL) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Biohaven had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 2 mentions for Biohaven and 1 mentions for Vigil Neuroscience. Biohaven's average media sentiment score of 0.84 beat Vigil Neuroscience's score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vigil Neuroscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biohaven
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vigil Neuroscience has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

83.6% of Vigil Neuroscience shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 18.0% of Vigil Neuroscience shares are owned by company insiders. Comparatively, 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vigil Neuroscience's return on equity of -111.70% beat Biohaven's return on equity.

Company Net Margins Return on Equity Return on Assets
Vigil NeuroscienceN/A -111.70% -74.67%
Biohaven N/A -257.07%-164.01%

Vigil Neuroscience is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.90
BiohavenN/AN/A-$846.42M-$9.36-1.56

Vigil Neuroscience currently has a consensus target price of $10.80, suggesting a potential upside of 35.17%. Biohaven has a consensus target price of $58.46, suggesting a potential upside of 299.60%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Vigil Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vigil Neuroscience
0 Sell rating(s)
10 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Biohaven
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
3.07

Summary

Biohaven beats Vigil Neuroscience on 8 of the 14 factors compared between the two stocks.

Get Vigil Neuroscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIGL vs. The Competition

MetricVigil NeuroscienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$381.02M$2.88B$5.49B$9.02B
Dividend YieldN/A2.43%5.38%4.09%
P/E Ratio-3.9021.5627.4720.28
Price / SalesN/A244.81408.86121.41
Price / CashN/A41.9536.6357.47
Price / Book4.577.518.095.67
Net Income-$84.26M-$55.05M$3.17B$248.96M
7 Day Performance0.50%4.61%2.81%3.30%
1 Month Performance1.14%4.89%3.67%5.20%
1 Year Performance102.28%5.84%35.41%21.37%

Vigil Neuroscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIGL
Vigil Neuroscience
3.3678 of 5 stars
$7.99
+0.1%
$10.80
+35.2%
+102.3%$381.02MN/A-3.9040
BHVN
Biohaven
3.4335 of 5 stars
$14.44
-0.2%
$58.46
+305.0%
-56.7%$1.47BN/A-1.54239
ETNB
89BIO
1.9513 of 5 stars
$10.00
-0.8%
$26.43
+164.3%
+35.6%$1.46BN/A-2.9640
ANIP
ANI Pharmaceuticals
3.7371 of 5 stars
$66.03
+0.7%
$80.13
+21.3%
+7.4%$1.43B$614.38M-51.99600
VERA
Vera Therapeutics
3.5568 of 5 stars
$21.65
+3.8%
$65.00
+200.2%
-31.9%$1.38BN/A-7.2240Positive News
JANX
Janux Therapeutics
1.8263 of 5 stars
$22.88
-3.1%
$95.25
+316.3%
-36.3%$1.35B$10.59M-16.8230
EVO
Evotec
1.7448 of 5 stars
$3.81
+1.3%
$5.93
+55.7%
-18.5%$1.35B$788.22M0.004,827News Coverage
Positive News
OCUL
Ocular Therapeutix
3.8077 of 5 stars
$8.37
+3.0%
$17.33
+107.1%
+39.9%$1.33B$63.72M-7.28230
MESO
Mesoblast
2.406 of 5 stars
$10.16
-2.7%
$18.00
+77.2%
+58.6%$1.30B$5.90M0.0080Positive News
TVTX
Travere Therapeutics
3.2429 of 5 stars
$14.49
+1.3%
$32.14
+121.8%
+88.9%$1.29B$233.18M-5.16460Analyst Forecast
Analyst Revision
BGM
BGM Group
N/A$13.12
+0.4%
N/AN/A$1.28B$25.10M0.00298High Trading Volume

Related Companies and Tools


This page (NASDAQ:VIGL) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners